Bank of New York Mellon’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bank of New York Mellon's AMLX Position: Q2 2026 in Review

Bank of New York Mellon increased its Amylyx Pharmaceuticals (AMLX) stake by 9.3% in Q2 2026, buying an estimated $361K and bringing the position to 274,435 shares worth $4.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Bank of New York Mellon first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $7.76M in Q4 2022. 58 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

• Bank of New York Mellon held 274,435 shares of Amylyx Pharmaceuticals worth $4.93M as of Q2 2026.
• Bank of New York Mellon bought 23,331 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $361K.
• Amylyx Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2448 holding.
• Bank of New York Mellon first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
• Bank of New York Mellon's Amylyx Pharmaceuticals position peaked at $7.76M in Q4 2022.
• 58 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.